Conversely, the inhibition of the intrinsic pathway, e.g., by inhibiting FXI/XIa, represents a promising approach, especially in high-risk patient populations for both bleeding and thromboembolism, such as patients with ESKD on HD.33 The gene discussed is F11; the disease is Thromboembolism.